Data Sheet 1_Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonis

169,630 propensity-score-matched patient cohorts from the TriNetX US Collaborative Network were followed for up to 4 years to assess skin disease risks. The study emulated a randomized trial to compare glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is) for patients with type 2 diabetes. Author Yi-Lun Chiang published the results under a CC-BY-4.0 license in April 2026.

Use Cases

• Assessing the association between GLP-1 RA initiation and incident psoriasis based on hazard ratios.
• Evaluating the reduced risk of pemphigus and bullous pemphigoid associated with GLP-1 RAs compared to DPP-4is.
• Conducting subgroup and sensitivity analyses for dermatologic safety outcomes in a real-world setting.
• Emulating a target trial design to inform incretin therapy selection and skin monitoring protocols.

Strengths

• Large-scale study with 169,630 patients in each balanced cohort after propensity score matching.
• Follow-up period of up to 4 years for newly diagnosed skin diseases.
• Study design addresses protopathic bias by excluding outcomes within 3 months of drug initiation.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying raw data is unknown, which may limit suitability assessment.
• Data may reflect geographic and temporal bias inherent to the TriNetX US Collaborative Network.

Provenance

Source

TriNetX US Collaborative Network.

Collection Method

Target trial emulation using 1:1 propensity score matching on electronic health records.

Time Range

Drug initiations between January 1, 2018, and December 31, 2022, with follow-up for up to 4 years.

Freshness

Last updated 2026-04-13 04:35:17; freshness should be verified.

Geography

United States.